SITUS JUDI MBL77 - AN OVERVIEW

If FCR will be the treatment of preference, caution needs to be taken in people with NOTCH1 mutations, in whom rituximab appears to get minimal additional value.59 Other genomic subgroups, which include individuals with BIRC3 mutations seem to derive very little gain from CIT,111,112 but these final results needs to be even more validated.Jika Anda